Approval · Notice of Compliance 24924 · 2021
MVASI: Notice of Compliance 24924
Issued January 5, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24924
- Date
- January 5, 2021
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer
- Canadian reference product
- AVASTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MVASI | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 25 MG per ML
- BEVACIZUMAB 100 MG per 4ML